Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.

Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.

Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.

While the legal woes over the seeds giant Monsanto continue, the German group's pharmaceuticals business posts unspectacular third quarter results.